Publicacions en què col·labora amb RAQUEL RIVERA DÍAZ (14)

2024

  1. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry

    British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363

  2. Upadacitinib for the management of overlapping psoriasis and atopic dermatitis: a case series

    International Journal of Dermatology

2022

  1. Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406

  2. Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness

    Expert Opinion on Biological Therapy

  3. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry

    Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117

  4. Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study

    Journal of Dermatological Treatment, Vol. 33, Núm. 3, pp. 1329-1338

2021

  1. Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort

    Acta dermato-venereologica, Vol. 101, Núm. 1, pp. adv00354

  2. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

    Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517

  3. Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study

    Journal of the European Academy of Dermatology and Venereology

2020

  1. COVID-19 and systemic therapies in psoriasis: experience of a tertiary hospital in Madrid

    International Journal of Dermatology

  2. Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry

    Actas Dermo-Sifiliograficas, Vol. 111, Núm. 9, pp. 752-760

  3. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry

    Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150

  4. Necrobiosis lipoídica: una manifestación más de la diabetes mellitus. (Pag. e51-e52)

    Semergen: revista española de medicina de familia, Núm. 6, pp. 440-440

  5. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study

    Journal of the American Academy of Dermatology, Vol. 82, Núm. 3, pp. 738-741